Recombinant Anti-CD89 x Anti-EGFR Bispecific Antibody (Miniantibody) is a fusion protein of two scFv fragments combined with distinct specificity. One scFv of an anti-CD89 antibody variable domain is linked to another scFv of an anti-EGFR antibody variable domain by a flexible hinge region. This BsAb format has the decreased size and better penetration than conventional IgGs in the clinical diagnostics and potentially therapy. This BsAb can retarget macrophages to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Non-small cell lung cancer (NSCLC); Solid tumors therapy.